

The X Siena Think Tank
A Vision of I-O: call to action

The Think Tank is promoted by the NIBIT Foundation in collaboration with the Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council

October 8-10, 2026

Rationale

The X Think Tank of the Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation is focused on sharing with the enlarged scientific community the research findings and initiatives of the **NIBIT Foundation** research team in the context of the rapidly evolving field of cancer immunotherapy worldwide. A great opportunity of professional exchange and scientific update for all participants.

As for the past editions, the Meeting is organized in collaboration with **The Parker Institute for Cancer Immunotherapy (PICI)** in San Francisco and the **World Immunotherapy Council (WIC)**.

During the event world-wide acknowledged scientists in the field of cancer immunotherapy will debate about pre-selected scientific, translational and clinical research topics, engaging the attendees in highly interactive discussions.

Aims of the meeting will be:

1. Sharing the vision on highly selected I-O topics
2. Implementing new collaborations (pre-clinical/clinical/educational) among participants and with the organizational (and financial) support of the scientific Co-Organizing entities
3. Presenting research projects/ideas by pre-selected (also through WIC) young investigators in the identified topics of the meeting to be discussed and eventually hosted in Institutions participating to the Think Tank.
4. Generating a white paper manuscript

October 8th

18:00 - 18:10 Welcome to the X Siena I-O Think Tank

Michele Maio (Siena, Italy), Bernie Fox (Portland, USA), Ramy Ibrahim (Siena, Italy)

18:10 - 20:00 Opening Session: Celebrating 10 years of our Siena I-O Think Tank

Chairs: Bernie Fox (Portland, USA), Ramy Ibrahim (Siena, Italy), Michele Maio (Siena, Italy)

18:10 - 18:20 A patient story 10 years later - Andrea Bifarini (Terni, Italy)

18:20 - 19:10 Ten years of the Siena Think Tank and its contribution to my vision, collaborations, and achievements in I-O

Led by Ramy Ibrahim (Siena, Italy) and Patrick Garcia (GSK, Switzerland)

Panelists: Bernie Fox (Providence, USA), Ramy Ibrahim (Siena, Italy), Michele Maio (Siena, Italy), Aiman Shalabi (GSK, USA), Zlatko Trajanosky (Innsbruck, Austria), Michael Lahn (iOnctura, Switzerland), Patrick Garcia (GSK, Switzerland), Wolf Hervé Fridman (Paris, France), Alexander Eggermont (Utrecht, The Netherlands)

19:10 - 19:30 The analyst view for the next decade of I-O - Asthika Goonewardene (Leerink Partners, New York, USA)

19:30 - 20:00 The growing complexity of TLS: from morphology to functionality and location - Wolf Hervé Fridman (Paris, France)

20:30 Wine and Cheese: Toast to the 10th Anniversary and to the future of the Siena I-O Think Tank

October 9th

SESSION 1 - 09:00 - 13:00 Focus on the PICI and NIBIT Foundation research: opportunities for joint actions?

09:00 - 09:15 *Chairs: Ramy Ibrahim (Siena, Italy), Lorenzo Moretta (Rome, Italy), Michele Maio (Siena, Italy)*

09:15 - 09:45 PICI: Evolving Cytokine Therapy in Oncology: Next-Generation Allosteric Agonists for Targeted Immune Modulation - John Connolly (San Francisco, USA)

09:45 - 10:15 PICI: T Cell Engagers in Advanced Prostate Cancer - Sumit Subudhi (Houston, USA)

10:15 - 10:45 PICI: Mapping the antitumor immune response against melanoma -
Katie Campbell (Los Angeles, USA)

10:45 - 11:15 Coffee Break

11:15 - 11:45 NIBIT Foundation/EPICA Consortium: Epigenetic immune reprogramming overcomes PD-1 resistance in metastatic melanoma patients: the phase II NIBIT ML-1 trial - Anna Maria Di Giacomo (Siena, Italy)

11:45 - 12:15 NIBIT Foundation/EPICA Consortium: Transient reactivation of immune and transposable-element programs underlies response to epigenetic-based immunotherapy - Teresa Noviello (Miami, USA)

12:15 - 12:45 EPICA Consortium: Peripheral immune profiling for discovery of predictive biomarkers of response vs resistance to epigenetic-based immunotherapy in melanoma - Andrea Anichini (Milan, Italy)

12:45 - 13:00 Conclusions and call to action - Chairs

13:00 - 14:00 Lunch

SESSION 2 - 14:00 - 16:00 Driving I-O therapy with liquid biopsy

14:00 - 14:15 *Chairs: Barbara Seliger (Halle/Brandenburg, Germany), Anna Maria Di Giacomo (Siena, Italy), Francesco Dotta (Rome, Italy)*

14:15-14:45 ctDNA to guide and monitor immunotherapy: are we ready for prime time? - Umberto Malapelle (Naples, Italy)

14:45-15:15 Knowledge-informed multimodal cfDNA analysis improves sensitivity and generalization in cancer detection- Michele Ceccarelli (Miami, USA)

15:15-15:45 Seromics to monitor dark matter vaccinated patients - Bernard A. Fox (Providence, USA)

15:45 - 16:00 Conclusions and call to action - Chairs

16:00 - 16:30 Tea Break

SESSION 3 - 16:30 - 19:10 Difficult to treat tumors with I-O

16:30 - 16:45 *Chairs: Michael Weller (Zürich, Switzerland), Paola Nisticò (Rome, Italy), Luana Calabrò (Ferrara, Italy)*

16:45 - 17:15 Understanding the limits of immunotherapy in Head and Neck Squamous Cell Carcinoma. From biological barriers to clinical trial designs - Marco Merlano (Turin, Italy)

17:15 - 17:45 Double intrathecal immune checkpoint inhibition for leptomeningeal metastasis from melanoma and non-small lung cancer: the IT-IO trial - Emilie Le Ruhn (Zürich, Switzerland)

17:45 - 18:15 Reframing TGF β inhibition through a macrophage-centered lens: lessons from clinical trials in pancreatic cancer - Davide Melisi (Verona, Italy)

18:15 - 18:30 **Conclusions and call to action** - Chairs

18:30 - 19:10 **The NIBIT Foundation Annual Lecture:** Targeted immunotherapy with PD-1 blockade - Antoni Ribas (Los Angeles, USA)

Introduced by Alexander Eggermont (Utrecht, The Netherlands)

20:30 - Social Dinner

October 10th

SESSION 4 - 08:45 - 10:45 Novel therapeutic strategies in pre-clinical and early clinical development

08:45 - 09:00 *Chairs: Patrick Garcia (GSK, Switzerland), Roberto Camerini (Rome, Italy), Pedro Romero (Lausanne, Switzerland)*

09:00 - 09:30 The state of oncology through the lens of deals and IPOs - Sam Fazeli (Bloomberg, UK)

09:30 - 09:50 Bispecific T-cell engagers: an early look at solid tumor development - Dennis Yoon (Regeneron, USA)

09:50 - 10:10 Antibody-drug conjugates through an immunological lens - Gargi Patel (GSK, USA)

10:10-10:30 How the Think Tank contributed to unlocking the mystery of finding a safe PI3kdelta inhibitor - Michael Lahn (iOnctura, Switzerland)

10:30 - 10:45 **Conclusions and call to action** - Chairs

10:45 - 11:00 *Coffee Break*

SESSION 5 - 11:00 - 13:30 Novel technologies to dissect the tumor-host ecosystem: single-cells, spatial transcriptomics and AI

11:00 - 11:15 *Chairs: Zlatko Trajanoski (Innsbruck, Austria), Elisabetta Ferretti (Rome, Italy), Catherine Sautes-Fridman (Paris, France)*

11:15 - 11:45 Single-cell TCRs, decoded: a pan-cancer atlas of shared, immune dominant antigens - Diether Lambrechts (Leuven, Belgium)

11:45 - 12:15 Directing TCR T cell therapies to new targets - Johanna Olweus (Oslo, Norway)

12:15 - 12:45 Dissecting and rewiring immune cell activity in human cancer tissues - Daniela Thommen (Amsterdam, The Netherlands)

12:45 -13:15 Human metagenomics applications in oncology - Nicola Segata (Trento, Italy)

13:15 - 13:30 Conclusions and call to action - Chairs

13:30 - 13:45 SESSION 6 - The XI Siena I-O Think Tank 2027

Chairs: Michele Maio (Siena, Italy), Bernie Fox (Portland, USA), Ramy Ibrahim (Siena, Italy)

Ideas and topics for the XI Siena 2027 Think Tank (October 7-9, 2027)

FACULTY 2026

- Andrea Anichini (Milan, Italy)
- Andrea Bifarini (Terni, Italy)
- Luana Calabrò (Ferrara, Italy)
- Roberto Camerini (Rome, Italy)
- Katie Campbell (Los Angeles, USA)
- Michele Ceccarelli (Miami, USA)
- John Connolly (San Francisco, USA)
- Anna Maria Di Giacomo (Siena, Italy)
- Francesco Dotta (Rome, Italy)
- Alexander Eggermont (Utrecht, The Netherlands)
- Sam Fazeli (Bloomberg, London, UK)
- Elisabetta Ferretti (Rome, Italy)
- Bernard A. Fox (Providence, USA)
- Wolf Hervé Fridman (Paris, France)
- Patrick Garcia (GlaxoSmithKline, Switzerland)
- Asthika Goonewardene (Leerink Partners, New York, USA)
- Ramy Ibrahim (Siena, Italy)

- Michael Lahn (iOnctura, Switzerland)
- Diether Lambrechts (Leuven, Belgium)
- Emilie Le Ruhn (Zurich, Switzerland)
- Michele Maio (Siena, Italy)
- Umberto Malapelle (Naples, Italy)
- Davide Melisi (Verona, Italy)
- Marco Merlano (Turin, Italy)
- Lorenzo Moretta (Rome, Italy)
- Paola Nisticò (Rome, Italy)
- Teresa Noviello (Miami, USA)
- Johanna Olweus (Oslo, Norway)
- Gargi Patel (GlaxoSmithKline, USA)
- Antoni Ribas (Los Angeles, USA)
- Pedro Romero (Lausanne, Switzerland)
- Catherine Sautès-Fridman (Paris, France)
- Nicola Segata (Trento, Italy)
- Barbara Seliger (Halle/Brandenburg, Germany)
- Aiman Shalabi (GlaxoSmithKline, USA)
- Sumit Subudhi (Houston, USA)
- Daniela Thommen (Amsterdam, The Netherlands)
- Zlatko Trajanoski (Innsbruck, Austria)
- Michael Weller (Zurich, Switzerland)
- Dennis Yoon (Regeneron, USA)

INVITEE FACULTY

- Sergio Abrignani (Milan, Italy)
- Maresa Altomonte (Siena, Italy)
- Leonardo Aversa (Vancouver, Canada)
- Gustavo Baldassarre (Rome, Italy)
- Daniele Banfi (Milan, Italy)
- Angelo Bellisario (Bristol Myers Squibb, Italy)
- Jennifer Burbea (Rome, Italy)
- Elisabetta Calabrese (Bristol Myers Squibb, Italy)
- Sandra Coral (Siena, Italy)
- Giorgio Costacurta (Pordenone, Italy)
- Alessia Covre (Siena, Italy)
- Rossella Dragonetti (Rome, Italy)
- Massimo Ferro (Immunocore, Italy)
- Elisabetta Fratta (Aviano, Italy)
- Maria Lofiego (Siena, Italy)
- Daniela Massi (Florence, Italy)
- Roberto Molinaro (XGEN Venture, Italy)
- Roberta Mortarini (Milan, Italy)
- Carlo Pucillo (Udine, Italy)

- Francesco Rao (Bristol Myers Squibb, Italy)
- Rino Rappuoli (Siena, Italy)
- Gaetano Romano (OncoTargets and Therapy, United Kingdom)
- Luca Sigalotti (Aviano, Italy)

SCIENTIFIC ORGANIZERS

Michele Maio - University of Siena and Center for Immuno-Oncology, Siena (Italy)

Bernie Fox - Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland (USA)

Ramy Ibrahim - University of Siena and Center for Immuno-Oncology, Siena (Italy)